

BIO IMAGING TECHNOLOGIES INC  
Form SC 13D  
November 12, 2008

---

---

OMB APPROVAL  
OMB  
Number: 3235-0145  
Expires: February  
28, 2009  
Estimated average  
burden  
H o u r s p e r  
response 14.5

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D

INFORMATION TO BE INCLUDED IN STATEMENTS FILED  
PURSUANT TO §240.13d-1(a) AND AMENDMENTS THERETO  
FILED PURSUANT TO §240.13d-2(a)  
(Amendment No. \_)\*

Bio-Imaging Technologies, Inc.

-----  
(Name of Issuer)

Common Stock

-----  
(Title of Class of Securities)

09056N103

-----  
(CUSIP Number)

Healthinvest Partners AB  
Arsenalsgatan 4  
SE-111 47 Stockholm  
Sweden  
Tel. 011-46-8-440-38-31

With a copy to:  
Stephen P. Wink, Esq.

Cahill/Wink LLP  
5 Penn Plaza  
23rd Floor  
New York, NY 10001  
(646) 378-2105

-----  
(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

November 12, 2008

-----  
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]

-----  
 CUSIP No. 09056N103  
 -----

1 Name of Reporting Persons  
 Healthinvest Partners AB

2 Check the Appropriate Box if a Member of a Group (See Instructions)  
 (a)  [ ]  
 (b)  [X]

3 SEC Use Only

4 Source of Funds (See Instructions)  
 WC

5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)  [ ]

6 Citizen or Place of Organization  
 Sweden

Number of 7 Sole Voting Power 756,893

Shares Beneficially 8 Shared Voting Power 0

Owned by Each 9 Sole Dispositive Power 756,893

Reporting Person With: 10 Shared Dispositive Power 0

11 Aggregate Amount Beneficially Owned by Each Reporting Person

756,893

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares  
 (See Instructions)  [ ]

13 Percent of Class Represented by Amount in Row (11)

5.3%

14 Type of Reporting Person (See Instructions)

IA, HC



-----  
 CUSIP No. 09056N103  
 -----

1 Name of Reporting Persons  
 HealthInvest Global Long/Short Fund  
 -----

2 Check the Appropriate Box if a Member of a Group (See Instructions)  
 (a)    
 (b)    
 -----

3 SEC Use Only  
 -----

4 Source of Funds (See Instructions)  
 WC  
 -----

5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)    
 -----

6 Citizen or Place of Organization  
 Sweden  
 -----

Number of 7 Sole Voting Power 0  
 -----

Shares Beneficially 8 Shared Voting Power 756,893  
 -----

Owned by Each 9 Sole Dispositive Power 0  
 -----

Reporting Person With: 10 Shared Dispositive Power 756,893  
 -----

11 Aggregate Amount Beneficially Owned by Each Reporting Person  
 -----

756,893  
 -----

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares  
 (See Instructions)    
 -----

13 Percent of Class Represented by Amount in Row (11)  
 -----

5.3%  
 -----

14 Type of Reporting Person (See Instructions)  
 -----

OO  
 -----



Item 1 Security and Issuer

The class of equity to which this statement relates is the common stock, \$0.00025 par value (the “Common Stock”), of Bio-Imaging Technologies, Inc. (the “Company”), which has its principal executive offices at:

826 Newtown-Yardley Road  
Newtown, Pennsylvania 18940-1721

Item 2 Identity and Background

The names of the persons filing this statement are Healthinvest Partners AB, a Swedish corporation, and HealthInvest Global Long/Short Fund, a specialty fund organized pursuant to the Swedish Mutual Funds Act (each, a “Reporting Person”).

Healthinvest Partners AB and HealthInvest Global Long/Short Fund are engaged in the business of investment management. Healthinvest Partners AB is the investment advisor and control person of Healthinvest Global Long/Short Fund, a security holder of the issuer.

The address of the principal office of each of the Reporting Persons is Arsenalsgatan 4, SE-111 47 Stockholm, Sweden.

During the last five years, neither of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 3 Source and Amount of Funds or Other Consideration

The Reporting Persons acquired the 756,893 shares of Common Stock to which this Statement relates with investment capital held by HealthInvest Global Long/Short Fund as follows:

(a) HealthInvest Global Long/Short Fund acquired 756,893 shares of Common Stock on the open market between November 6, 2006 and November 10, 2008 for a total consideration of \$3,700,832.

The above amount of total consideration includes any commissions incurred in making the investments. The source of these funds was the investment capital of the Reporting Persons, which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business.





Item 4 Purpose of Transaction

All of the shares of Common Stock reported herein were acquired for investment purposes, and were originally acquired without the purpose or effect of changing or influencing control of the Company. The Reporting Persons review on a continuing basis the investment in the Company. Based on such review and depending on the price and availability of the Company's securities, the Reporting Persons may acquire, or cause to be acquired, additional securities of the Company, in the open market or otherwise, dispose of, or cause to be disposed of, securities of the Company, in the open market or otherwise, at any time, or formulate other purposes, plans or proposals regarding the Company or any of its securities, to the extent deemed advisable in light of general investment and policies of the Reporting Persons, the Company's business, financial condition and operating results, general market and industry conditions or other factors.

As part of the ongoing evaluation of this investment and investment alternatives, the Reporting Persons and their affiliates may consider any or all of the following: (a) the acquisition by any person of additional securities of the Company, or the disposition of securities of the Company; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Company or any of its subsidiaries; (d) any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board of directors; (e) any material change in the present capitalization or dividend policy of the Company; (f) any other material change in the Company's business or corporate structure; (g) changes in the Company's charter or bylaws or other actions which may impede the acquisition of control of the Company by any person; (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) causing a class of equity securities of the Company to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated above.

In addition, from time to time, the Reporting Persons and their affiliates may hold discussions with the Company regarding the matters described in subparagraphs (a) through (j) above.

On November 12, 2008, Anders Hallberg, the Managing Director and CEO of Healthinvest Partners AB, sent a letter to the Chairman of the Board of Directors of the Company and the Company's Chief Executive Officer expressing, among other things, displeasure with the Company's deteriorating shareholder value during 2008 and, in particular, the Company's continued operation of the poorly performing CapMed division. Mr. Hallberg urged the Board and management of the Company to dispose of the CapMed division through divestiture or shutdown. A copy of such letter is attached hereto as Exhibit 99.2 and incorporated by reference herein.

Item 5 Interest in Securities of the Issuer

(a) As of the close of business on November 11, 2008, Healthinvest Partners AB and HealthInvest Global Long/Short Fund were the beneficial owners of 756,893 shares of Common Stock, which constitute in the aggregate 5.3% of the outstanding shares of Common Stock of the Company, based on 14,341,403 shares of Common Stock outstanding as reported on the Form 10-Q for the quarterly period ending September 30, 2008 filed by the Company.

(b) Healthinvest Partners AB has the sole power to vote, direct the voting of, dispose of and direct the disposition of the Common Stock owned by it as described in Item 5(a) above.

Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form SC 13D

HealthInvest Global Long/Short Fund has shared power to vote, direct the vote of, dispose of and direct the disposition of the Common Stock owned by it as described in Item 5(a) above. Such power is shared with Healthinvest Partners AB.

(c) Transactions in the Common Stock by the Reporting Persons effected in the last 60 days are as set forth in the table below. All such trades were made in open market transactions.

Entity	Trade Date	Activity	Quantity	Average Price
HealthInvest Global Long/Short Fund	09/15/08	BUY	27,800	7.69
HealthInvest Global Long/Short Fund	09/19/08	BUY	25,000	7.71
HealthInvest Global Long/Short Fund	09/29/08	BUY	8,300	7.14
HealthInvest Global Long/Short Fund	09/30/08	BUY	30,000	7.43
HealthInvest Global Long/Short Fund	10/06/07	BUY	10,000	6.00
HealthInvest Global Long/Short Fund	10/06/08	BUY	10,000	6.00
HealthInvest Global Long/Short Fund	10/13/08	BUY	10,000	5.80
HealthInvest Global Long/Short Fund	10/15/08	BUY	60,000	5.66
HealthInvest Global Long/Short Fund	10/24/08	BUY	25,000	5.01
HealthInvest Global Long/Short Fund	10/30/08	BUY	10,000	4.08
HealthInvest Global Long/Short Fund	10/31/08	BUY	25,000	4.10
HealthInvest Global Long/Short Fund	11/07/08	BUY	97,806	2.56
HealthInvest Global Long/Short Fund	11/07/08	BUY	3,900	2.67
HealthInvest Global Long/Short Fund	11/10/08	BUY	100,000	2.81

(d) The Reporting Persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock owned by them.

(e) Not applicable.

Item 6 Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

None.

Item 7 Material to be Filed as Exhibits

99.1 Joint Filing Agreement

99.2 Letter dated November 12, 2008 from Anders Hallberg, Managing Director and CEO of Healthinvest Partners AB, to the Chairman of the Board of Directors of the Company and the Company's Chief Executive Officer.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATE: November 12, 2008  
HEALTHINVEST PARTNERS AB

By: /s/ ANDERS HALLBERG

Name: Anders Hallberg  
Title: Managing Director and CEO

HEALTHINVEST GLOBAL LONG/SHORT FUND

By: /s/ ANDERS HALLBERG

Name: Anders Hallberg  
Title: CEO of Managing Company

